Evidence map›Paper›PMID 33941831›Full record

ArticleScientific reports2021

Epilepsy lifetime prevalence in Iran: a large population- based national survey.

Hossein Pakdaman, Ali Amini Harandi, Koroush Gharagozli, Farshid Alaeddini, Akram Esfandani, Seyed Hamidreza Mirbehbahani, Taher Doroudi, Pirhossein Kolivand, Parviz Bahrami, Hadi Kazemi

Abstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. National and subnational burden of neurological disorders in Iran, 1990 to 2021: results from the global burden of disease study 2021.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Hossein PakdamanBrain Mapping Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Ali Amini HarandiBrain Mapping Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. ali.amini.harandi@gmail.com.
Koroush GharagozliBrain Mapping Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Farshid AlaeddiniBrain Mapping Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Akram EsfandaniBrain Mapping Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Seyed Hamidreza MirbehbahaniBrain Mapping Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Taher DoroudiShefa Neuroscience Research Center, Khatam-Ol-Anbia Hospital, Tehran, Iran.
Pirhossein KolivandShefa Neuroscience Research Center, Khatam-Ol-Anbia Hospital, Tehran, Iran.
Parviz BahramiShefa Neuroscience Research Center, Khatam-Ol-Anbia Hospital, Tehran, Iran.
Hadi KazemiShefa Neuroscience Research Center, Khatam-Ol-Anbia Hospital, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epilepsy has garnered increased public health focus because patients who suffer from epilepsy experience pronounced and persistent health and socioeconomic disparities despite treatment and care advances. The epidemiology of epilepsy is diverse in different countries and regions. This nationwide population-based cross-sectional study was conducted to determine the life time prevalence and health related factors of epilepsy for the first time in Iran through a two-phase door-to-door survey method. In phase I, a screening for epilepsy was performed on 68,035 people. Then in phase II, after the neurological evaluation of participants and reviewing medical records, 1130 subjects with epilepsy was confirmed. The life time prevalence of epilepsy was achieved to be 16.6 per 1000 people (95% CI 15.4-17.8) with the average age onset 19.1 ± 21.1 (active prevalence 9.5 per 1000 people). Focal seizure (59.3%), generalized epilepsy (38%) and unknown types of epilepsy (2.7%) were detected among participants. The overall life time prevalence of febrile convulsion was 4.1 per 1000 people. The frequency of attacks per year and per month were 3.0 ± 1.6 and 0.5 ± 0.1, respectively. Age-specific life time prevalence was highest among the age group of 15-19 years old [32.7 per 1000 persons (95% CI 29.1-36.8)] and it was higher in male (53.8%) than female (46.2%) participants. Our results showed that the life time prevalence of epilepsy in Iran is higher than worldwide average.

Indexed as

Mass ScreeningAdolescentAdultAgedAged, 80 and overAge FactorsAnticonvulsantsChildChild, PreschoolCross-Sectional StudiesEpilepsyFemaleHealth StatusHealth SurveysHumansInfantAnticonvulsants

Identifiers

PMID33941831
PMCPMC8093423

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.